Bioxytran moves A-SUQAR towards Gulf sales after securing export paperwork

Bioxytran, Inc has taken a first administrative step towards selling its A-SUQAR chewable tablet in the Gulf, announcing on 4 November 2026 that it holds a government-issued Free Sale Certificate for the product. The company has not put a figure on the commercial opportunity, and it gave no sales forecast or deal terms.

A-SUQAR is a dietary supplement meant to be taken before meals, with the aim of dampening the rise in blood sugar that follows eating. According to Bioxytran, the certificate has been legalised by the foreign ministry of the country that issued it and prepared for attestation for use in the UAE. The summary of the announcement does not identify the issuing authority or the country.

The company said it and its distribution partner intend to begin product registration in the UAE. They also plan to assess regulatory routes in Saudi Arabia, Kuwait and other Gulf Cooperation Council markets. Bioxytran said when A-SUQAR reaches shelves will depend on local regulatory requirements, and no filings or timelines for those other countries have been announced. The partner was not named in the material available to us.

By way of context, a Free Sale Certificate is commonly requested by importing countries to show that a product can be sold freely in its home market. It usually forms one element of a larger registration dossier and does not amount to approval in its own right, so the UAE process remains to be completed.